196 related articles for article (PubMed ID: 37014080)
1. Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study.
Barata PC; Leith A; Ribbands A; Montgomery R; Last M; Arondekar B; Ivanova J; Niyazov A
Oncologist; 2023 Sep; 28(9):780-789. PubMed ID: 37014080
[TBL] [Abstract][Full Text] [Related]
2. Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study.
Barata PC; Leith A; Ribbands A; Montgomery R; Last M; Arondekar B; Ivanova J; Niyazov A
Oncologist; 2023 Sep; 28(9):e737-e747. PubMed ID: 37014097
[TBL] [Abstract][Full Text] [Related]
3. Treatment Intensification Patterns and Utilization in Patients with Metastatic Castration-Sensitive Prostate Cancer.
Heath EI; Dyson GE; Cackowski FC; Hafron J; Powell I
Clin Genitourin Cancer; 2022 Dec; 20(6):524-532. PubMed ID: 35864053
[TBL] [Abstract][Full Text] [Related]
4. Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data.
Freedland SJ; Ke X; Lafeuille MH; Romdhani H; Kinkead F; Lefebvre P; Petrilla A; Pulungan Z; Kim S; D'Andrea DM; Francis P; Ryan CJ
Curr Med Res Opin; 2021 Apr; 37(4):609-622. PubMed ID: 33476184
[TBL] [Abstract][Full Text] [Related]
5. Real-World Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Across Europe (France, Germany, Italy, Spain, and the United Kingdom) and Japan.
Leith A; Kim J; Ribbands A; Clayton E; Yang L; Ghate SR
Adv Ther; 2022 May; 39(5):2236-2255. PubMed ID: 35316501
[TBL] [Abstract][Full Text] [Related]
6. Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting.
Sayegh N; Tripathi N; Nussenzveig RH; Thomas VM; Tandar C; Goel D; Nordblad B; Sahu KK; Li H; L Maughan B; Agarwal N; Swami U
Eur Urol Focus; 2023 Jan; 9(1):106-109. PubMed ID: 35835693
[TBL] [Abstract][Full Text] [Related]
7. A Real-World Evidence Study Using Alberta-Population-Based Data to Describe Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer Patients (AWARENESS).
Karim S; Lowther J; Gyulay G; O'Sullivan D; Wallis CJD; Yip SM; Brenner DR; Boyne DJ; Cheung WY
Curr Oncol; 2023 Sep; 30(9):8149-8158. PubMed ID: 37754506
[TBL] [Abstract][Full Text] [Related]
8. Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer.
Dandapani SV; Wong J; Twardowski P
Cancer Biother Radiopharm; 2020 Sep; 35(7):490-496. PubMed ID: 32762539
[No Abstract] [Full Text] [Related]
9. Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.
Ryan CJ; Ke X; Lafeuille MH; Romdhani H; Kinkead F; Lefebvre P; Petrilla A; Pulungan Z; Kim S; D'Andrea DM; Francis P; Freedland SJ
J Urol; 2021 Dec; 206(6):1420-1429. PubMed ID: 34293915
[TBL] [Abstract][Full Text] [Related]
10. Current status and future perspective on the management of metastatic castration-sensitive prostate cancer.
Blas L; Shiota M; Eto M
Cancer Treat Res Commun; 2022; 32():100606. PubMed ID: 35835707
[TBL] [Abstract][Full Text] [Related]
11. Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer.
Graf RP; Fisher V; Mateo J; Gjoerup OV; Madison RW; Raskina K; Tukachinsky H; Creeden J; Cunningham R; Huang RSP; Mata DA; Ross JS; Oxnard GR; Venstrom JM; Zurita AJ
Eur Urol; 2022 Jan; 81(1):37-47. PubMed ID: 34716049
[TBL] [Abstract][Full Text] [Related]
12. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis.
Ciccarese C; Iacovelli R; Sternberg CN; Gillessen S; Tortora G; Fizazi K
Eur J Cancer; 2022 Sep; 173():276-284. PubMed ID: 35964470
[TBL] [Abstract][Full Text] [Related]
13. SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
Swami U; Graf RP; Nussenzveig RH; Fisher V; Tukachinsky H; Schrock AB; Li G; Ross JS; Sayegh N; Tripathi N; Mathew Thomas V; Oxnard GR; Antonarakis ES; Agarwal N
Clin Cancer Res; 2022 Nov; 28(22):4917-4925. PubMed ID: 36088616
[TBL] [Abstract][Full Text] [Related]
14. Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer.
Grisay G; Lavaud P; Fizazi K
Curr Oncol Rep; 2024 May; 26(5):488-495. PubMed ID: 38592590
[TBL] [Abstract][Full Text] [Related]
15. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population.
Freedland SJ; Davis M; Epstein AJ; Arondekar B; Ivanova JI
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):327-333. PubMed ID: 37783836
[TBL] [Abstract][Full Text] [Related]
16. The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate Cancer.
Swami U; Hong A; El-Chaar NN; Ramaswamy K; Diessner BJ; Blauer-Peterson CJ; Sandin R; Nimke D; Agarwal N
J Urol; 2023 Jun; 209(6):1120-1131. PubMed ID: 36789668
[TBL] [Abstract][Full Text] [Related]
17. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
18. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.
Hafron JM; Wilfehrt HM; Ferro C; Harmon M; Flanders SC; McKay RR
Adv Ther; 2022 Jun; 39(6):2515-2532. PubMed ID: 35352309
[TBL] [Abstract][Full Text] [Related]
19. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets.
Kappel C; Jiang DM; Wong B; Zhang T; Selvarajah S; Warner E; Hansen AR; Fallah-Rad N; Sacher AG; Stockley TL; Bedard PL; Sridhar SS
Clin Genitourin Cancer; 2022 Jun; 20(3):278-284. PubMed ID: 35337750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]